October 16, 2001 - Here are some of the press releases concerning dialysis and nephrology-related studies presented at the annual meetings of the American Society of Nephrology and the International Society of Nephrology this week in San Francisco:

A study on �Better Survival Rates On Dialysis For Patients With Higher Body Mass Index� was presented by researchers at the University of Texas Medical Branch in Galveston, Texas. Here is a summary from Doctor�s Guide.

Preliminary data was presented, suggesting that a monthly dose of Aranesp, a longer-lasting version of Amgen's anemia drug, was shown to be effective when administered once a month. Here is a news article from Yahoo Finance.

"The B-Cell Toleragen� LJP 394 reduces renal flares in patients with lupus nephritis: A prospective double-blinded, placebo- controlled trial" was presented by La Jolla Pharmaceutical Company. Here is a summary from Doctor�s Guide.

Data from two studies were presented on the topic of improved ultrafiltration and control of weight gain by using Extraneal (7.5% icodextrin), a peritoneal dialysis solution. Here is a summary from Doctor�s Guide.

Researchers at the University of Toronto, in Toronto, Ontario, Canada, presented their findings on dialysis patients who receive their treatment at night may have less cardiac enlargement and high blood pressure. Here is a summary from Doctor�s Guide.

Researchers at the University of Michigan, at Ann Arbor, presented their findings on �Mycophenolate Mofetil Shows Efficacy for Pediatric Steroid-Dependent Nephrotic Syndrome�. Here is a summary from Doctor�s Guide.


[This message has been edited by Gary Peterson (edited 10-16-2001).]